Tenofovir was approved by food and drug administration (FDA) for treatment of chronic B hepatitis in 2008. To evaluate the primary efficacy of Tenofovir, 305 patients treated by Topjlovir (26 cases), Planovir (12 cases), Tenofovir Stada (138 cases) and Getino-B (129 cases) were enrolled in this study. HBV DNA, AST, ALT, total Bilirubin were measured at 0,1,3,6, 12,24,30,36 months of the course of therapy. Results showed that 155/305 (50.8 percent) patients were treated by one of following antiviral drugs: Lamivudine, Adefovir or Entecavir. Level of HBV DNA before of treatment was 4.5 x 10 exponent 8 + or - 2.3 x 10 exponent 3 copies/ml. After 1 month of therapy of Tenofovir, 305/305 (100 percent) patients have HBV DNA decreased at least 210g, with 280/305 (91.8 percent) patients decreased more than 310g; After 3 months of therapy 275/305 (90.16 percent) patients have HBV DNA 100 copies/ml; After 6 months of therapy 295/305 (96.7 percent) have HBV DNA 100 copies/ml. Mean of follow up was 18 months (6-36 months) without any antiviral resistance, side effect was observed. There is no significant difference between Topjlovir, Planovir, Tenofovir Stada and Getino-B in treatment for chronic B hepatitis. Thus, Tenofovir is an efficacy medication for treatment of chronic B hepatitis.
- Đăng nhập để gửi ý kiến